- Home
- ABUS vs MAZE Comparison
ABUS vs MAZE Comparison
Compare ABUS & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- MAZE
- Stock Information
- Founded
- ABUS 2005
- MAZE 2018
- Country
- ABUS United States
- MAZE United States
- Employees
- ABUS N/A
- MAZE N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- MAZE
- Sector
- ABUS Health Care
- MAZE
- Exchange
- ABUS Nasdaq
- MAZE NYSE
- Market Cap
- ABUS 592.8M
- MAZE 523.1M
- IPO Year
- ABUS N/A
- MAZE 2025
- Fundamental
- Price
- ABUS $3.24
- MAZE $9.55
- Analyst Decision
- ABUS Strong Buy
- MAZE Strong Buy
- Analyst Count
- ABUS 4
- MAZE 3
- Target Price
- ABUS $5.50
- MAZE $25.67
- AVG Volume (30 Days)
- ABUS 1.3M
- MAZE 225.6K
- Earning Date
- ABUS 05-05-2025
- MAZE 01-01-0001
- Dividend Yield
- ABUS N/A
- MAZE N/A
- EPS Growth
- ABUS N/A
- MAZE N/A
- EPS
- ABUS N/A
- MAZE 1.25
- Revenue
- ABUS $6,171,000.00
- MAZE $167,500,000.00
- Revenue This Year
- ABUS $14.57
- MAZE N/A
- Revenue Next Year
- ABUS $15.84
- MAZE N/A
- P/E Ratio
- ABUS N/A
- MAZE $7.89
- Revenue Growth
- ABUS N/A
- MAZE N/A
- 52 Week Low
- ABUS $2.63
- MAZE $6.71
- 52 Week High
- ABUS $4.72
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- ABUS 50.09
- MAZE N/A
- Support Level
- ABUS $2.71
- MAZE N/A
- Resistance Level
- ABUS $3.32
- MAZE N/A
- Average True Range (ATR)
- ABUS 0.21
- MAZE 0.00
- MACD
- ABUS 0.00
- MAZE 0.00
- Stochastic Oscillator
- ABUS 63.86
- MAZE 0.00
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.